Showing Results for: “Glycemic Index and Diabetes”

Linagliptin, when added to usual diabetes care in people with type 2 diabetes (T2D) with increased risk of cardiovascular (CV) and/or renal disease, resulted in incidences of CV and renal events comparable to placebo over a median period of 2.2 years across a broad range of age and kidney function status, according to a symposium presentation today titled “Linagliptin Trial in Type 2 Diabetes Mellitus at High Cardiovascular Risk with Chronic Kidney Disease,” at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® at the Moscone Convention Center in San Francisco

New research shows that daily oral vitamin D supplementation does not effectively reduce the risk of type 2 diabetes among vitamin D-sufficient adults at high risk for developing the disease, according to the “The Vitamin D and Type 2 Diabetes (D2d) Study – A Multicenter Randomized Controlled Trial for Diabetes Prevention” study presented today at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® at the Moscone Convention Center in San Francisco. More than 84 million Americans have prediabetes, which is a precursor of symptoms indicating higher risk of progression to type

There are currently more than 37 million American adults living with diabetes. Almost three times that many adults (96 million) are living with prediabetes and 90% are completely unaware. Anyone with diabetes is at risk for diabetes-related eye diseases such as diabetic retinopathy, macular edema, glaucoma, and cataracts. Some groups, however, are at a higher risk of losing their vision or going blind from diabetes, including Black Americans, Hispanics and Latinos, American Indians, and Alaska Natives. While genetic factors likely play a role in these health inequities, so do social, economic

“La Asociación Americana de la Diabetes (ADA) es la principal defensora de la asequibilidad de la insulina y trabaja para garantizar que todas las personas con diabetes tengan acceso a la atención que necesitan. La ADA ha liderado el proceso de aprobación de límites de gastos compartidos para la insulina en 22 estados y en el Distrito de Columbia, así como el primer límite federal de copago en Medicare. Nos alienta que los principales fabricantes hayan tomado medidas para que la insulina sea más asequible, pero la lucha no ha terminado. Seguiremos defendiendo los esfuerzos en el Congreso y en

In a comparison of two different diet and two different weight management programs, results of the international PREVIEW intervention study found a low, similar rate of progression to type 2 diabetes (T2D) among people with prediabetes who had initially lost weight on a low-calorie diet (LCD), according to a symposium presentation today titled “PREVIEW Study Results—Prevention of Diabetes through Lifestyle Intervention and Population Studies Around the World” at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® in San Francisco. The study showed no difference between

The American Diabetes Association® (ADA) will present the 2019 Kelly West Award for Outstanding Achievement in Epidemiology to Elizabeth J. Mayer-Davis, PhD. This award recognizes significant contributions to the field of diabetes epidemiology. Dr. Mayer-Davis will be recognized with this honor at the ADA’s 79th Scientific Sessions, June 7-11, 2019, at the Moscone Convention Center in San Francisco. She will deliver her Kelly West Award Lecture titled, “ Improving Outcomes—Translating Epidemiology to Clinical Trials ,” on Sunday, June 9. Dr. Mayer-Davis is currently the Cary C. Boshamer